164 related articles for article (PubMed ID: 11127848)
1. Systemic endothelial cell markers in primary antiphospholipid syndrome.
Williams FM; Parmar K; Hughes GR; Hunt BJ
Thromb Haemost; 2000 Nov; 84(5):742-6. PubMed ID: 11127848
[TBL] [Abstract][Full Text] [Related]
2. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis.
Kaplanski G; Cacoub P; Farnarier C; Marin V; Grégoire R; Gatel A; Durand JM; Harlé JR; Bongrand P; Piette JC
Arthritis Rheum; 2000 Jan; 43(1):55-64. PubMed ID: 10643700
[TBL] [Abstract][Full Text] [Related]
3. Patients with antiphospholipid syndrome display endothelial perturbation.
Cugno M; Borghi MO; Lonati LM; Ghiadoni L; Gerosa M; Grossi C; De Angelis V; Magnaghi G; Tincani A; Mari D; Riboldi P; Meroni PL
J Autoimmun; 2010 Mar; 34(2):105-10. PubMed ID: 19656656
[TBL] [Abstract][Full Text] [Related]
4. Statins for the treatment of antiphospholipid syndrome?
Jajoria P; Murthy V; Papalardo E; Romay-Penabad Z; Gleason C; Pierangeli SS
Ann N Y Acad Sci; 2009 Sep; 1173():736-45. PubMed ID: 19758223
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory response and the endothelium.
Meroni PL; Borghi MO; Raschi E; Ventura D; Sarzi Puttini PC; Atzeni F; Lonati L; Parati G; Tincani A; Mari D; Tedesco F
Thromb Res; 2004; 114(5-6):329-34. PubMed ID: 15507262
[TBL] [Abstract][Full Text] [Related]
6. [Soluble P-selectin - a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension].
Semenov AV; Kogan-Ponomarev MIa; Ruda MIa; Komarov AL; Panchenko EP; Chazova IE; Mazurov AV
Ter Arkh; 2000; 72(4):15-20. PubMed ID: 10833791
[TBL] [Abstract][Full Text] [Related]
7. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study.
Butthep P; Bunyaratvej A; Funahara Y; Kitaguchi H; Fucharoen S; Sato S; Bhamarapravati N
Southeast Asian J Trop Med Public Health; 1997; 28 Suppl 3():141-148A. PubMed ID: 9640617
[TBL] [Abstract][Full Text] [Related]
8. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function.
Gresele P; Migliacci R; Vedovati MC; Ruffatti A; Becattini C; Facco M; Guglielmini G; Boscaro E; Mezzasoma AM; Momi S; Pengo V
Thromb Res; 2009; 123(3):444-51. PubMed ID: 18617225
[TBL] [Abstract][Full Text] [Related]
9. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers.
Blann AD; Lip GY; Beevers DG; McCollum CN
Thromb Haemost; 1997 Jun; 77(6):1077-80. PubMed ID: 9241735
[TBL] [Abstract][Full Text] [Related]
10. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease.
Tsakiris DA; Tschöpl M; Wolf F; Labs KH; Jäger KA; Marbet GA
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):165-73. PubMed ID: 10759010
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor.
Wei LH; Kuo ML; Chen CA; Cheng WF; Cheng SP; Hsieh FJ; Hsieh CY
Gynecol Oncol; 2001 Jul; 82(1):49-56. PubMed ID: 11426961
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor synergistically enhances induction of E-selectin by tumor necrosis factor-alpha.
Stannard AK; Khurana R; Evans IM; Sofra V; Holmes DI; Zachary I
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):494-502. PubMed ID: 17170373
[TBL] [Abstract][Full Text] [Related]
14. Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients.
Grooteman MP; Gritters M; Wauters IM; Schalkwijk CG; Stam F; Twisk J; Ter Wee PM; Nubé MJ
Nephrol Dial Transplant; 2005 Dec; 20(12):2751-8. PubMed ID: 16188898
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease.
Stinghen AE; Gonçalves SM; Martines EG; Nakao LS; Riella MC; Aita CA; Pecoits-Filho R
Nephron Clin Pract; 2009; 111(2):c117-26. PubMed ID: 19147993
[TBL] [Abstract][Full Text] [Related]
17. Normal expression of cell adhesion molecules in placentae from women with systemic lupus erythematosus and the antiphospholipid syndrome.
Lakasing L; Campa JS; Parmar K; Poston R; Hunt BJ; Poston L
Placenta; 2000; 21(2-3):142-9. PubMed ID: 10736236
[TBL] [Abstract][Full Text] [Related]
18. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes.
O'Malley T; Ludlam CA; Riemermsa RA; Fox KA
Eur Heart J; 2001 Jul; 22(14):1226-34. PubMed ID: 11440495
[TBL] [Abstract][Full Text] [Related]
19. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome.
Walenga JM; Michal K; Hoppensteadt D; Wood JJ; Robinson JA; Bick RL
Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S76-84. PubMed ID: 10726041
[TBL] [Abstract][Full Text] [Related]
20. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.
Klimiuk PA; Sierakowski S; Domysławska I; Fiedorczyk M; Chwiećko J
Arch Immunol Ther Exp (Warsz); 2004; 52(1):36-42. PubMed ID: 15053231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
